The PEDVAC trial: Preliminary data from the first therapeutic DNA vaccination in HIV-infected children

Vaccine

Volumn 29, Issue 39, 2011, Pages 6810-6816

  Palma, Paolo ^a,b   Romiti, Maria Luisa ^a   Li Pira, Giuseppina ^b,c   Montesano, Carla ^a   Mora, Nadia ^a,b   Aquilani, Angela ^a   Santilli, Veronica ^a   Tchidjou, Hyppolite K ^a,b   Ivaldi, Federico ^d   Giovannelli, Luigi ^b   Pontrelli, Giuseppe ^b   Borra, Giada ^a   Blomberg, Pontus ^e   Gudmundsdotter, Lindvi ^f   Bråve, Andreas ^f   Montano, Marco ^a   Bernardi, Stefania ^b   Manca, Fabrizio ^d   Wahren, Britta ^f   Rossi, Paolo ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^c Advanced Biotechnology Center   (Italy)

^d G GASLINI INSTITUTE   (Italy)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Children; HIV; Multigene HIV DNA vaccine; Therapeutic vaccine

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS RNA;

ADOLESCENT; ARTICLE; BODY MOVEMENT; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILD; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DIARRHEA; DNA IMMUNIZATION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; INJECTION SITE ERYTHEMA; INJECTION SITE HYPERSENSITIVITY; INJECTION SITE INDURATION; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; LYMPHADENOPATHY; LYMPHOCYTE PROLIFERATION; MALE; MYALGIA; NAUSEA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; SINGLE BLIND PROCEDURE; SKIN REDNESS; SORE THROAT; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; VOMITING;

ADOLESCENT; AIDS VACCINES; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; DRUG EVALUATION; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INJECTIONS, INTRAMUSCULAR; INTERFERON-GAMMA; MALE; VACCINATION; VACCINES, DNA; VIRAL LOAD;

EID: 79955523128     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.12.058     Document Type: Article

References (41)

1. De Martino M., Tovo P.A., Balducci M., Galli L., Gabbiano C., Rezza G., et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. JAMA 2000, 284:190-197.
2. Patel K., Hernán M.A., Williams P.L., Seeger J.D., McIntosh K., Dyke R.B., et al. Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV:5 years and counting. Clin Infect Dis 2008, 46(11):1751-1760.
3. Palma P., Romiti M.L., Cancrini C., Pensieroso S., Montesano C., Santucci M.B., et al. Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV. AIDS 2007, 21(18):2465-2472.
4. Prendergast A., Tudor-Williams G., Jeena P., Burchett S., Goulder P. International perspectives, progress, and future challenges of paediatric HIV infection. Lancet 2007, 370(9581):68-80.
5. McComsey G.A., Leonard E. Metabolic complications of HIV therapy in children. AIDS 2004, 18(13):1753-1768.
6. Leonard E.G., McComsey G.A. Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival. Infect Dis Clin North Am 2005, 19(3):713-729.
7. El-Sadr W.M., Lundgren J.D., Neaton J.D., Gordin F., Abrams D., Arduino R.C., et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006, 355(22):2283-2296. Strategies for Management of Antiretroviral Therapy (SMART) Study Group.
8. Paediatric European Network for Treatment of AIDS Response to planned treatment interruptions in HIV infection varies across childhood. AIDS 2010, 24(2):231-241.
9. Lu W., Arraes L.C., Ferreira W.T., Andrieu J.M. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 2004, 10(12):1359-1365.
10. Gudmundsdotter L., Sjödin A., Boström A.C., Hejdeman B., Theve-Palm R., Alaeus A., et al. Therapeutic immunization for HIV. Springer Semin Immunopathol 2006, 28(3):221-230.
11. Gandhi R.T., O'Neill D., Bosch R.J., Chan E.S., Bucy R.P., Shopis J., et al. A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine 2009, 27(43):6088-6094.
12. Montagnier L. 25 years after HIV discovery: prospects for cure and vaccine. Virology 2010, 397(2):248-254.
13. Sandström E., Wahren B. Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group. Lancet 1999, 353(9166):1735-1742.
14. Kutzler M.A., Weiner D.B. DNA vaccines: ready for prime time?. Nat Rev Genet 2008, 9(10):776-788.
15. Catanzaro A.T., Roederer M., Koup R.A., Bailer R.T., Enama M.E., Nason M.C., et al. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 2007, 25(20):4085-4092.
16. Rollman E., Bråve A., Boberg A., Gudmundsdotter L., Engström G., Isaguliants M., et al. The rationale behind a vaccine based on multiple HIV antigens. Microbes Infect 2005, 7(14):1414-1423.
17. Devito C., Zuber B., Schröder U., Benthin R., Okuda K., Broliden K., et al. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity. J Immunol 2001, 173(11):7078-7089.
18. Hinkula J., Devito C., Zuber B., Benthin R., Ferreira D., Wahren B., et al. A novel DNA adjuvant, N3, enhances mucosal and systemic immune responses induced by HIV-1 DNA and peptide immunizations. Vaccine 2006, 24(21):4494-4497.
19. Buonaguro L., Devito C., Tornesello M.L., Schröder U., Wahren B., Hinkula J., et al. DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. Vaccine 2007, 25(32):5968-5977.
20. Bråve A., Boberg A., Gudmundsdotter L., Rollman E., Hallermalm K., Ljungberg K., et al. A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in mice. Mol Ther 2007, 15(9):1724-1733.
21. Sandström E., Nilsson C., Hejdeman B., Bråve A., Bratt G., Robb M., et al. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis 2008, 198(10):1482-1490.
22. Ljungberg K., Rollman E., Eriksson L., Hinkula J., Wahren B. Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes. Virology 2002, 302:44-57.
23. Bråve A., Ljungberg K., Boberg A., Rollman E., Engström G., Hinkula, et al. Reduced cellular immune responses following immunization with a multi-gene HIV-1 vaccine. Vaccine 2006, 24(21):4524-4526.
24. Food and Drug Administration. Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. Available from: http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074775.htm.
25. Pensieroso P., Romiti M.L., Palma P., Castelli-Gattinare G., Bernardi S., Freda E., et al. Switching from PI-based-HAART to PI-sparing regimen is associated with improved specific HIV-immune responses in HIV-infected children. AIDS 2006, 20:1893-1896.
26. Li Pira G., Ivaldi F., Bottone L., Manca F. High throughput functional microdissection of pathogen-specific T-cell immunity using antigen and lymphocyte arrays. J Immunol Methods 2007, 326(1-2):22-32.
27. Li Pira G., Ivaldi F., Dentone C., Righi E., Del Bono V., Viscoli C., et al. Evaluation of antigen-specific T-cell responses with a miniaturized and automated method. Clin Vaccine Immunol 2008, 15(12):1811-1818.
28. Li Pira G., Ivaldi F., Moretti P., Risso M., Tripodi G., Manca F. Validation of a miniaturized assay based on IFN-g secretion for assessment of specific T cell immunity. J Immunol Methods 2010, 355(1-2):68-75.
29. Sprangers M.C., Lakhai W., Koudstaal W., Verhoeven M., Koel B.F., Vogels R., et al. Quantifying adenovirus neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol 2003, 41:5046-5052.
30. Harro C.D., Robertson M.N., Lally M.A., O'Neill L.D., Edupuganti S., Goepfert P.A., et al. Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults. AIDS Res Hum Retroviruses 2009, 25:103-114.
31. Koup R.A., Roederer M., Lamoreaux L., Fischer J., Novik L., Nason M.C., et al. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One 2010, 5(2):e9015.
32. Leandersson A.C., Gilljam G., Fredriksson M., Hinkula J., Alaeus A., Lidman K., et al. Cross-reactive T-helper responses in patients infected with different subtypes of human immunodeficiency virus type 1. J Virol 2000, 74(10):4888-4890.
33. Casimiro D.R., Chen L., Fu T.M., Evans R.K., Caulfield M.J., Davies M.E., et al. Comparative immunogenicity of rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003, 77:6305-6313.
34. Priddy F.H., Brown D., Kublin J., Monahan K., Wright D.P., Lalezari J., et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Merck V520-016 Study Group. Clin Infect Dis 2008, 46:1769-1781.
35. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test of-concept trial. Lancet 2008, 372:1881-1893.
36. Asmuth D.M., Brown E.L., DiNubile M.J., Sun X., del Rio C., Harro C., et al. Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens. J Infect Dis 2010, 201(1):132-141.
37. Palma P., Romiti M.L., Cancrini C., Pensieroso S., Montesano C., Bernardi S., et al. Delayed early antiretroviral treatment is associated with an HIV-specific long-term cellular response in HIV-1 vertically infected infants. Vaccine 2008, 26(40):5196-5201.
38. Pensieroso S., Cagigi A., Palma P., Nilsson A., Capponi C., Freda E., et al. Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children. Proc Natl Acad Sci USA 2009, 106(19):7939-7944.
39. McElrath M.J., De Rosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., et al. HIV-1 vaccine-induced immunity in the test-of-concept StepStudy: a case-cohort analysis. Lancet 2008, 372(9653):1881-1893.
40. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361(23):2209-2220.
41. Kern F., Li Pira G., Gratama J.W., Manca F., Roederer M. Measuring Ag-specific immune responses: understanding immunopathogenesis and improving diagnostics in infectious disease, autoimmunity and cancer. Trends Immunol 2005, 26(9):477-484.